These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1774434)

  • 21. Experimental autoimmune encephalomyelitis in the maturing central nervous system. Transfer of myelin basic protein-specific T line lymphocytes to neonatal Lewis rats.
    Umehara F; Qin YF; Goto M; Wekerle H; Meyermann R
    Lab Invest; 1990 Feb; 62(2):147-55. PubMed ID: 1689408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
    Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor.
    Jacobs CA; Baker PE; Roux ER; Picha KS; Toivola B; Waugh S; Kennedy MK
    J Immunol; 1991 May; 146(9):2983-9. PubMed ID: 1826702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis.
    Javed NH; Gienapp IE; Cox KL; Whitacre CC
    J Immunol; 1995 Aug; 155(3):1599-605. PubMed ID: 7543526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig.
    Brod SA; al-Sabbagh A; Sobel RA; Hafler DA; Weiner HL
    Ann Neurol; 1991 Jun; 29(6):615-22. PubMed ID: 1716432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
    Jönsson S; Andersson G; Fex T; Fristedt T; Hedlund G; Jansson K; Abramo L; Fritzson I; Pekarski O; Runström A; Sandin H; Thuvesson I; Björk A
    J Med Chem; 2004 Apr; 47(8):2075-88. PubMed ID: 15056005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis.
    Gold DP; Schroder K; Powell HC; Kelly CJ
    Eur J Immunol; 1997 Nov; 27(11):2863-9. PubMed ID: 9394811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli.
    Nieuwenhuis EE; Visser MR; Kavelaars A; Cobelens PM; Fleer A; Harmsen W; Verhoef J; Akkermans LM; Heijnen CJ
    Arthritis Rheum; 2000 Nov; 43(11):2583-9. PubMed ID: 11083284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of experimental allergic encephalomyelitis in rats by suppressor factor from a permanent T cell line.
    Stĕdra J; Holán V; Lodin Z
    Folia Biol (Praha); 1986; 32(3):212-7. PubMed ID: 3488925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic control of the development of experimental allergic encephalomyelitis in rats. Separation of MHC and non-MHC gene effects.
    Happ MP; Wettstein P; Dietzschold B; Heber-Katz E
    J Immunol; 1988 Sep; 141(5):1489-94. PubMed ID: 2457618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic experimental autoimmune encephalomyelitis induced by the 89-101 myelin basic protein peptide in B10RIII (H-2r) mice.
    Jansson L; Olsson T; Höjeberg B; Holmdahl R
    Eur J Immunol; 1991 Mar; 21(3):693-9. PubMed ID: 1707002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
    Ohta Y; Fukuda S; Makino H
    Immunopharmacology; 1997 Oct; 37(2-3):167-74. PubMed ID: 9403335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of FCE 20696, a new synthetic immunomodulator, in models of viral and bacterial pathology.
    Verini MA; Ungheri D
    Immunopharmacology; 1989; 17(3):157-65. PubMed ID: 2475454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases.
    Carlson RP; Baeder WL; Caccese RG; Warner LM; Sehgal SN
    Ann N Y Acad Sci; 1993 Jun; 685():86-113. PubMed ID: 8363289
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes.
    Badger AM; Dimartino MJ; Talmadge JE; Picker DH; Schwartz DA; Dorman JW; Mirabelli CK; Hanna N
    Int J Immunopharmacol; 1989; 11(7):839-46. PubMed ID: 2532178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease.
    Ahlem C; Auci D; Mangano K; Reading C; Frincke J; Stickney D; Nicoletti F
    Ann N Y Acad Sci; 2009 Sep; 1173():781-90. PubMed ID: 19758229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunostimulatory properties of ethylene-2,2' -bis(dithio)bis(ethanol) and related compounds in vivo.
    Hiestand PC; Strasser M
    Int J Immunopharmacol; 1985; 7(1):141-51. PubMed ID: 3888866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of autoimmune disease and the generation of suppressor cells by spirogermanium: a biological profile similar to total lymphoid irradiation.
    Badger AM; Mirabelli CK; Swift BA; DiMartino MJ
    Agents Actions; 1989 Jun; 27(3-4):335-7. PubMed ID: 2529742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.
    Tarkowski A; Gunnarsson K; Nilsson LA; Lindholm L; Stålhandske T
    Arthritis Rheum; 1986 Nov; 29(11):1405-9. PubMed ID: 3778545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases.
    Schorlemmer HU; Dickneite G
    Ann N Y Acad Sci; 1993 Jun; 685():155-74. PubMed ID: 8363220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.